Myriad Genetics, SOPHiA partner on prostate cancer biomarker

Myriad Genetics (NASDAQ:MYGN) and SOPHiA GENETICS (NASDAQ:SOPH) are collaborating with AstraZeneca (NYSE:AZN) to advance prostate cancer biomarker PrGIS. Myriad's MyChoice CDx test will produce the PrGIS score, and SOPHiA will integrate it into its cloud-based platform. The companies plan to present research at ESMO 2026.

Original reporting
Published Oct 8, 2026, 1:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MYGN
Bullish
high confidence
Mentioned
$MYGN · $SOPH · $AZN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MYGNBullishMed
01

Why it matters

The partnership could create a new companion diagnostic market, potentially increasing revenues for Myriad and SOPHiA while offering AstraZeneca a tailored testing solution.

02

Market read

First‑time disclosure of a multi‑company oncology collaboration, offering a modest but actionable catalyst for the involved stocks.

03

What to watch

Regulatory approval timelines and reimbursement uncertainty could limit upside.

Relevance 7/10Novelty 7/10Timing: today

Background

The article reports a newly announced collaboration between three companies to develop a prostate cancer biomarker, with no prior public disclosure.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Myriad Genetics announced a new collaboration with SOPHiA Genetics and AstraZeneca to develop a prostate cancer biomarker.

Expected impact

likely upward pressure as market prices in the collaboration news

Evidence & confidence

First disclosure of a multi‑company partnership targeting a high‑need oncology indication.

$SOPHBullishHigh confidence
Context

SOPHiA Genetics joined Myriad Genetics and AstraZeneca to advance the PrGIS prostate cancer biomarker.

Expected impact

likely upward pressure as investors anticipate expanded diagnostic market

Evidence & confidence

First report of SOPHiA's involvement in a high‑profile oncology collaboration.

$AZNNeutralMedium confidence
Context

AstraZeneca partnered with Myriad Genetics and SOPHiA Genetics to advance a prostate cancer genomic instability score.

Expected impact

little immediate impact; potential upside if biomarker progresses

Evidence & confidence

AZN is a large pharma; the partnership is a small component of its broader pipeline.

Market effects

Strengthens the oncology diagnostics sector and may boost related biotech stocks.

Highlights European and US collaboration in precision oncology.

Adds to the pipeline of prostate cancer biomarkers, a globally relevant therapeutic area.

Counterpoint

The partnership may not translate into near‑term revenue; investors should watch for clinical trial milestones.

Key entities

  • Myriad Genetics

    US biotech developing the PrGIS biomarker.

  • SOPHiA Genetics

    Cloud‑based genomics platform expanding into prostate cancer diagnostics.

  • AstraZeneca

    Pharma partner providing clinical development expertise.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$AZNMed

A bump in the road for AstraZeneca's billion-dollar investment

Summit Therapeutics' stock fell 16% after FDA rejected ivonescimab for lung cancer, citing insufficient U.S. patient data. AstraZeneca, which invested $2B in Summit, awaits results from a global study (HARMONi-3) comparing ivonescimab to Merck's Keytruda. Analysts remain optimistic about Summit's prospects.

$AZNHigh

ATCC Biomanufacturing Center Opens in Virginia

Alexion, an AstraZeneca subsidiary, received FDA approval for Klygefa (gefurulimab) to treat generalized myasthenia gravis (gMG) in adult patients with anti-acetylcholine receptor antibodies. The approval follows positive Phase III trial results showing significant improvement in daily living activities compared to placebo. Klygefa is the first dual-binding nanobody C5 inhibitor, offering once-weekly subcutaneous self-administration.

$AZNMed

AstraZeneca Cancer Drug Gets FDA Priority Review After 42% Lower Death Risk

AstraZeneca's experimental cancer drug, sonesitatug vedotin, received FDA Priority Review after a Phase III trial showed a 42% lower death risk in patients with advanced gastric and related cancers. The drug is being reviewed for second-line and later treatments, with a decision expected in Q2 2027. AstraZeneca estimates 60% of relevant cancers express the required biomarker, potentially expanding the eligible patient population.

$AZNMed

AstraZeneca’s cancer drug gets FDA priority review for gastric cancer

AstraZeneca's (AZN) cancer drug, sonesitatug vedotin, received FDA Priority Review for treating advanced gastric and related cancers. The drug showed a 42% reduction in death risk in a Phase III trial, with median survival of 10.6 months vs. 6.4 months for other therapies. The FDA decision is expected in Q2 2027. The drug targets Claudin 18.2-positive tumors, affecting about 60% of gastric cancers and 7,500 U.S. patients annually.

$AZNMed

AstraZeneca’s sonesitatug vedotin BLA accepted for priority review

AstraZeneca's BLA for sonesitatug vedotin (Sone-Ve) has been accepted for Priority Review by the FDA for treating advanced gastric, GEJ, or EAC cancers with CLDN18.2 expression. The FDA action date is expected in Q2 2027, potentially offering significant treatment improvements. According to AstraZeneca, the drug could provide notable safety or efficacy benefits if approved.